Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
According to the American College of Physicians’ guideline, clinicians should prescribe testosterone treatment only to men with sexual dysfunction symptoms.
Study reveals an approximately 2-fold increased odds of venous thromboembolism associated with testosterone therapy in men with or without hypogonadism
